KR20180027213A - Composition for skin improvement containing Salvianolic acid C - Google Patents
Composition for skin improvement containing Salvianolic acid C Download PDFInfo
- Publication number
- KR20180027213A KR20180027213A KR1020160114536A KR20160114536A KR20180027213A KR 20180027213 A KR20180027213 A KR 20180027213A KR 1020160114536 A KR1020160114536 A KR 1020160114536A KR 20160114536 A KR20160114536 A KR 20160114536A KR 20180027213 A KR20180027213 A KR 20180027213A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- cosmetic composition
- present
- formula
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 230000006872 improvement Effects 0.000 title abstract description 40
- GCJWPRRNLSHTRY-VURDRKPISA-N Salvianolic acid C Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2C=C(OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-VURDRKPISA-N 0.000 title abstract description 36
- GCJWPRRNLSHTRY-UHFFFAOYSA-N Salvianolic acid C Natural products C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)=CC=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 GCJWPRRNLSHTRY-UHFFFAOYSA-N 0.000 title abstract description 36
- 230000000694 effects Effects 0.000 claims abstract description 49
- 239000002537 cosmetic Substances 0.000 claims abstract description 38
- 230000002087 whitening effect Effects 0.000 claims abstract description 34
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 29
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 26
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 229920001436 collagen Polymers 0.000 claims abstract description 25
- 230000037394 skin elasticity Effects 0.000 claims abstract description 25
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 21
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 20
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 20
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 73
- 230000037303 wrinkles Effects 0.000 claims description 37
- 239000000126 substance Substances 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000004480 active ingredient Substances 0.000 claims description 20
- 230000003078 antioxidant effect Effects 0.000 claims description 19
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000008234 soft water Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 21
- 206010061218 Inflammation Diseases 0.000 abstract description 13
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 6
- 230000001747 exhibiting effect Effects 0.000 abstract description 3
- 230000037331 wrinkle reduction Effects 0.000 abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 20
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 14
- 239000013641 positive control Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 11
- 229930003268 Vitamin C Natural products 0.000 description 11
- 235000013376 functional food Nutrition 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 235000019154 vitamin C Nutrition 0.000 description 11
- 239000011718 vitamin C Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000016942 Elastin Human genes 0.000 description 7
- 108010014258 Elastin Proteins 0.000 description 7
- 229920002549 elastin Polymers 0.000 description 7
- 230000007760 free radical scavenging Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- -1 salvianolic acid C compound Chemical class 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036252 glycation Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 241000058445 Celina Species 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 241000304195 Salvia miltiorrhiza Species 0.000 description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 229930015704 phenylpropanoid Natural products 0.000 description 2
- 125000001474 phenylpropanoid group Chemical group 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000521299 Deinocerites cancer Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229910000063 azene Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
본 발명은 살비아놀산 C(Salvianolic acid C)를 포함하는 화장료 조성물에 관한 것으로서, 보다 상세하게는 피부 미백, 피부 탄력 증진, 주름 개선, 보습, 항산화 또는 피부 트러블 개선 등의 우수한 효과를 가지는 화장료 조성물에 관한 것이다. 또한, 본 발명은 살비아놀산 C를 포함하는 식품 조성물 및 의약외품 조성물에 관한 것이다.The present invention relates to a cosmetic composition comprising salvianolic acid C, and more particularly to a cosmetic composition having excellent effects such as skin whitening, skin elasticity improvement, wrinkle improvement, moisturizing, antioxidant or skin trouble improvement . The present invention also relates to food compositions and quasi-drug compositions comprising salvianolic acid C.
일반적으로 알려진 미백 성분으로서, 코지산(Kojic acid) 또는 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민 C(L-Ascorbic acid) 또는 이들의 유도체와 각종 식물 추출물이 있다. 이들은 멜라닌 색소의 합성을 저해함으로써, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착증의 개선이 가능하다. 그러나 피부 적용 시, 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적인 효과를 기대할 수 없는 문제점이 있다.Commonly known whitening ingredients include substances inhibiting tyrosinase enzyme activity such as kojic acid or arbutin, hydroquinone, vitamin C (L-ascorbic acid) or derivatives thereof, various plant extracts . By inhibiting the synthesis of melanin pigment, they can brighten the skin tone to realize skin whitening, and it is possible to improve skin hypercholesterolemia such as stain or freckles due to ultraviolet rays, hormones or heredity. However, when applied to skin, there is a problem that the use amount is limited due to safety problems such as irritation and redness, or the effect is insignificant, so that a practical effect can not be expected.
콜라겐은 피부의 섬유아세포(Fibroblast)에서 생성되는 주요 기질 단백질로서 세포 외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포접착의 지탱, 세포 분할과 분화(유기체의 성장 혹은 상처 치유 시)의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광 노화에 의해 감소하며, 콜라겐을 분해하는 콜라게나제 효소 활성으로 콜라겐 감소가 촉진된다. 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다.Collagen is a major substrate protein produced in the fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical durability of the skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, cell division and differentiation (Induction of growth of an organism or wound healing) are known. Such collagen is reduced by photoaging by age and ultraviolet irradiation, and collagenase activity, which degrades collagen, promotes collagen reduction. This is known to be closely related to the formation of wrinkles in the skin.
또한, 엘라스틴(Elastin) 섬유는 콜라겐과 가교 결합을 형성하며 피부 탄력에 관여하고 있는 주름 생성에 중요한 피부 구성성분이다. 엘라스틴 섬유의 결핍과 응집, 엘라스틴 분해 효소인 엘라스타제(Elastase)의 활성도의 현격한 증가는 피부 주름 생성 요인 중의 하나로 밝혀지고 있다. 엘라스타제는 엘라스틴을 분해할 수 있는 유일한 효소로서 이에 대한 저해는 피부 주름 개선을 근본적으로 줄여줄 수 있다고 알려져있다.In addition, Elastin fiber forms crosslinks with collagen and is a skin constituent important for wrinkle formation involved in skin elasticity. The deficiency and aggregation of elastin fibers and the dramatic increase in the activity of the elastin degrading enzyme Elastase have been found to be one of the causes of skin wrinkles. Elastase is the only enzyme capable of degrading elastin, and inhibition of it is known to be able to radically reduce wrinkles.
아울러, 콜라겐 및 엘라스틴 섬유는 진피층 내의 수분 보유에 중요한 역할을 하는 기질 단백질로 이러한 기질 단백질이 수분을 흡착하며, 이들이 이루는 구조 내부에 수분 보유력을 높여 피부가 적정 수분을 함유한 상태를 유지할 수 있도록 해주며, 이를 통해 피부의 탄력을 유지하는데 관여한다고 알려져있다.In addition, collagen and elastin fibers are substrate proteins that play an important role in moisture retention in the dermal layer. These protein proteins adsorb moisture and increase the water holding capacity inside the structure to maintain the skin's proper moisture content. And it is known to be involved in maintaining the elasticity of the skin.
현재, 피부 탄력 증진 및 주름 개선 화장료로는 레티노이드, 아데노신, 동물태반유래 단백질, 클로렐라 추출물 등이 알려져 있다. 가장 잘 알려져 있는 레티놀은 콜라겐 합성을 촉진하며 엘라스타제 효소를 저해하는 물질이지만 불안정하며, 피부 적용 시 자극, 발적 등의 안전성 문제로 사용량의 제한이 있으며, 클로렐라 추출물 등은 효과가 미미하여 실질적으로 피부 탄력 증진 및 주름 개선 효과를 기대하기가 어렵다고 알려져 있다.At present, retinoids, adenosine, animal placenta-derived proteins, chlorella extract, and the like are known as cosmetics for improving skin elasticity and improving wrinkles. The best known retinol promotes collagen synthesis and is a substance that inhibits elastase enzyme, but it is unstable. When applied to the skin, there is a limitation in usage due to safety problems such as irritation and redness, and chlorella extract has little effect, It is known that it is difficult to expect the effect of improving elasticity and wrinkle.
당화(Glycation)는 일반적으로 효소의 관여 없이 일어나는 단백질 또는 지방에 포도당 또는 과당과 같은 단순당이 공유결합을 형성하는 반응을 의미한다. 최종당화산물의 축적은 단백질을 단단하고 더욱 부서지기 쉬운 상태로 변화시키며, 당화된 콜라겐은 진피층의 세포 외 기질에서 콜라겐이 적절한 구조를 형성하지 못하도록 함으로써 피부의 탄력을 잃게 하고 주름 생성을 촉진한다(Dyer, D. G. et al, The Journal of Clinical Investigation., 9, p. 2463, 1993). 또한 당화로 인해 생성된 최종당화산물은 갈색 빛을 띠는 물질로써, 피부 노화가 진행되면서 점차 얼굴빛이 노랗게 변하는 원인 물질로 생각되고 있으며, 특정 최종당화산물이 쌓일수록 피부에서 반사되는 반사 빛이 줄어든다고 알려져 있다(Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009). 당화를 억제하는 물질로 아미노구아니딘(Aminoguanidine), 피리독사민(Pyridoxamine), 아스피린(Aspirin) 등이 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 효과를 기대할 수 없는 문제점이 있다.Glycation generally refers to a reaction in which a simple sugar such as glucose or fructose forms a covalent bond to a protein or fat that occurs without involvement of the enzyme. The accumulation of the final glycation product converts the protein into a harder and more brittle state, and the glycated collagen prevents the collagen from forming a proper structure in the extracellular matrix of the dermal layer, thereby losing skin elasticity and promoting wrinkle formation Dyer, DG et al, The Journal of Clinical Investigation, 9, p. 2463, 1993). In addition, the final saccharification product produced by the saccharification is a brownish substance, which is considered to be a cause of yellowing of the face gradually as the skin ages, and as the specific final saccharification product accumulates, the reflection light reflected from the skin is reduced (Hiroshi, O. et al., Skin Research and Technology, 15, p. 496, 2009). Aminoguanidine, pyridoxamine, and aspirin are known to inhibit glycation. However, these substances are limited in their use due to the safety of the skin, There is a problem that can not be expected.
화장품은 피부를 보호하고 피부의 미화 및 청결을 위해 사용되는 제품이지만, 그 조성으로는 피부 보호 목적과는 상이한 성분들이 제품 형성을 위해 불가피하게 포함된다. 이러한 성분들로는 계면활성제, 방부제, 향료, 자외선 차단제, 색소뿐 아니라, 그 밖의 효능 및 효과를 부여하기 위한 여러 가지 성분들이 여기에 포함된다. 이들 성분은 일반적으로 피부에 염증이나 뾰루지, 부종 등 각종 트러블을 발생시키는 것으로 알려져 있다(Maibach. H. I., Contact Dermatitis, 6. 369-404, 1980). 또한, 체내로부터 배출되는 피지 및 땀, 화장품 성분 중의 지방산, 고급 알코올, 단백질 성분 등이 피부상에 존재하는 피부 상재균에 의해 독성이 강한 물질로 분해되어 이들에 의해 피부 염증이 유발될 수도 있으며, 태양으로부터 나오는 자외선에 의해서도 피부 염증이 유발된다는 것은 잘 알려진 사실이다.Cosmetics are products used to protect the skin and beautify and clean the skin, but the composition thereof inevitably includes ingredients that are different from the purpose of skin protection. These ingredients include surfactants, preservatives, fragrances, sunscreens, pigments, as well as various ingredients for imparting other efficacy and effects. These ingredients are generally known to cause skin irritation, rashes, swelling and other problems (Maibach, H., I. Contact Dermatitis, 6. 369-404, 1980). In addition, sebum and sweat discharged from the body, fatty acids in cosmetic ingredients, higher alcohols, protein components and the like may be decomposed into substances having high toxicity by the skin-on-ground bacteria existing on the skin, It is well known that skin inflammation is caused by ultraviolet rays from the sun.
염증 반응은 붉어짐(feeling of redness), 따끔거림(pricking feeling), 화끈거림(burning hotness), 팽윤(swelling), 조직의 변화와 같은 5가지 현상으로 나타나는데, 이는 해로운 주위 환경, 즉 세균과 같은 외부 물질의 침입과 기계적 손상으로부터 생체를 보호하려는 생리적인 반응이다. 이러한 염증현상은 여러 종류의 다형핵 백혈구(PMNs)와 면역 물질의 많은 증가를 초래하며, 이처럼 증가된 세포들은 염증성 세포 산물인 다양한 종류의 단백질 분해 효소와 사이토카인 등을 분비함으로써 치료 및 방어를 할 수 있게 해준다. 그러나, 이러한 작용은 인접해 있는 조직 세포와 비세포 성분들에 해로운 손상을 일으키기도 한다. 따라서, 적절한 조건 하에서는 염증 초기 상태가 지난 후 정상 기능을 되찾게 되지만, 염증을 자극하는 자극제가 없어지지 않거나 계속해서 만들어질 경우에는 결과적으로 만성 염증이 일어나게 되어 더욱더 심각한 조직의 손상을 가져온다.Inflammation reactions are manifested in five phenomena, such as feeling of redness, pricking feeling, burning hotness, swelling, and tissue changes, which may be caused by harmful environmental conditions, It is a physiological reaction to protect a living body from intrusion and mechanical damage. These inflammatory phenomena lead to a large number of polymorphonuclear leukocytes (PMNs) and immune substances, and these increased cells secrete a variety of inflammatory cell products, proteases and cytokines. I can do it. However, this action may cause harmful damage to adjacent tissue cells and non-cellular components. Therefore, under proper conditions, the normal function is restored after the initial state of inflammation. However, if irritant stimulating agents are not eliminated or continuously produced, chronic inflammation occurs as a result, resulting in more serious tissue damage.
한편, 살비아놀산 C(Salvianolic acid C)은 분자식 C26H20O10, 분자량 492.44를 가지는 페닐프로파노이드(Phenylpropanoids) 계열의 화합물로서, 살비아놀산 C(Salvianolic acid C) 또는 (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-1-benzofuran-4-yl]prop-2-enoyl]oxypropanoic acid로 명명된다. 단삼(Salvia miltiorrhiza Bge )으로부터 분리할 수 있으며, 피리딘, 메탄올, 에탄올 등의 용매에 녹는 것으로 알려져 있다.On the other hand, Salvianolic acid C is a compound of phenylpropanoids having a molecular formula of C 26 H 20 O 10 and a molecular weight of 492.44. Salvianolic acid C or salicylic acid C (2R) - 3- (3,4-dihydroxyphenyl) -2 - [(E) -3- [2- (3,4-dihydroxyphenyl) -7-hydroxy-1-benzofuran-4-yl] prop- 2-enoyl] oxypropanoic acid . Salvia (Salvia miltiorrhiza Bge ) and is known to dissolve in solvents such as pyridine, methanol, and ethanol.
이러한 배경하에, 본 발명자들은 피부 미백, 피부 탄력 증진, 주름 개선, 보습, 항산화 및 피부 트러블 개선 효과가 우수한 물질에 관하여 연구를 수행하였으며, 이에 살비아놀산 C를 유효성분으로 포함하는 조성물이 멜라닌 총량 감소, 콜라겐 합성 촉진, 엘라스타제 활성 저해, 항산화, 항염증 및 항당화 효과를 나타냄을 규명하여, 이를 활용한 화장료 조성물, 식품 조성물 및 의약외품 조성물을 완성하기에 이르렀다.Under these circumstances, the inventors of the present invention conducted studies on substances having excellent skin whitening, skin elasticity enhancement, wrinkle improvement, moisturizing, antioxidative and skin trouble improving effects, and the composition containing salvianolic acid C as an active ingredient, Collagen synthesis inhibition, inhibition of elastase activity, antioxidation, antiinflammation and anticarcinogenic effect, and the cosmetic composition, food composition and quasi-drug composition using the same were completed.
본 발명의 목적은 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다.An object of the present invention is to provide a cosmetic composition comprising salvianolic acid C represented by the general formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
구체적으로, 본 발명의 목적은 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공하는 것이다.Specifically, the object of the present invention is to provide a cosmetic composition for skin whitening comprising salvianolic acid C represented by the general formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물을 제공하는 것이다.More specifically, the object of the present invention is to provide a cosmetic composition for skin elasticity enhancement or wrinkle improvement comprising salvianolic acid C represented by the formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습용 화장료 조성물을 제공하는 것이다.More specifically, the object of the present invention is to provide a cosmetic composition for moisturizing the skin comprising salvianolic acid C represented by the general formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
또한 구체적으로, 본 발명의 목적은 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 트러블 개선용 화장료 조성물을 제공하는 것이다.More specifically, it is an object of the present invention to provide a cosmetic composition for skin trouble improvement comprising salvianolic acid C represented by the formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 다른 목적은 화학식 1로 표시되는 살비아놀산 C 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition comprising salvianolic acid C represented by the general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은 화학식 1로 표시되는 살비아놀산 C 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 의약외품 조성물을 제공하는 것이다.Another object of the present invention is to provide a quasi-drug composition comprising salvianolic acid C represented by the general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명은 상기와 같은 과제들을 해결하고, 본 발명의 목적을 달성하기 위하여 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 화장료 조성물을 제공한다.The present invention provides cosmetic compositions comprising the compound represented by the formula (I) or a cosmetically acceptable salt thereof in order to solve the above-mentioned problems and to achieve the object of the present invention.
구체적으로, 본 발명의 하나의 양태로서, 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공한다.Specifically, as one embodiment of the present invention, there is provided a skin whitening cosmetic composition comprising salvianolic acid C represented by the general formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 다른 양태로서, 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물을 제공한다.In another aspect of the present invention, there is provided a cosmetic composition for skin elasticity enhancement or wrinkle improvement comprising salvianolic acid C represented by the general formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 양태로서, 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습용 화장료 조성물을 제공한다.As another embodiment of the present invention, there is provided a cosmetic composition for skin moisturizing comprising salvianolic acid C represented by the general formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 양태로서, 화학식 1로 표시되는 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 트러블 개선용 화장료 조성물을 제공한다.As another embodiment of the present invention, there is provided a cosmetic composition for skin trouble improvement comprising salvianolic acid C represented by the formula (1) or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 양태로서, 살비아놀산 C 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 식품 조성물을 제공한다.In another aspect of the present invention, there is provided a food composition comprising salvianolic acid C or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 양태로서, 살비아놀산 C 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 의약외품 조성물을 제공한다.In another aspect of the present invention, there is provided a quasi-drug composition comprising salvianolic acid C or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에서는 하기 화학식 1로 표시되는 살비아놀산 C 화합물 또는 이의 염을 포함하는 조성물을 제공한다.The present invention provides a composition comprising salvianolic acid C compound represented by the following general formula (1) or a salt thereof.
[화학식 1] [Chemical Formula 1]
본 발명에 있어서, “살비아놀산 C(Salvianolic acid C)”은 상기 화학식 1로 표시되고, 분자식 C26H20O10, 분자량 492.44를 가지며, 살비아놀산 C(Salvianolic acid C) 또는 (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-1-benzofuran-4-yl]prop-2-enoyl]oxypropanoic acid로 명명된다. 단삼(Salvia miltiorrhiza Bge )으로부터 분리할 수 있으며, 페닐프로파노이드(Phenylpropanoids) 로 분류되는 유기화합물이다. In the present invention, " salvianolic acid C " is represented by the above formula (1) and has a molecular formula C 26 H 20 O 10 , a molecular weight of 492.44, Salvianolic acid C or (2R) 3- (3,4-dihydroxyphenyl) -2 - [(E) -3- [2- (3,4-dihydroxyphenyl) -7-hydroxy-1-benzofuran-4-yl] prop- 2-enoyl] oxypropanoic acid. Salvia (Salvia miltiorrhiza Bge ) and is an organic compound classified as phenylpropanoids.
본 발명은 살비아놀산 C의 획득 방법에 특별히 한정되지 않으며, 당업계에 공지된 방법으로 화학적으로 합성하거나, 시판되는 물질을 사용할 수 있다.The present invention is not particularly limited to the method for obtaining salvianolic acid C, and may be chemically synthesized by a method known in the art, or a commercially available substance may be used.
본 발명의 화학식 1로 표시되는 살비아놀산 C는 용매화된 형태뿐만 아니라 비-용매화된(unsolvated) 형태로 존재할 수도 있다. 본 발명의 살비아놀산 C는 결정형 또는 무정형 형태로 존재할 수 있으며, 이러한 모든 물리적 형태는 본 발명의 범위에 포함된다.Salvianolic acid C represented by the formula (1) of the present invention may exist not only in a solvated form but also in an unsolvated form. Salvianolic acid C of the present invention may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.
본 발명에 따른 조성물에 있어, 상기 살비아놀산 C의 함량은 조성물 전체 중량 대비 0.0001 내지 10 중량% 인 것이 바람직하다.In the composition according to the present invention, the content of salvianolic acid C is preferably 0.0001 to 10% by weight based on the total weight of the composition.
본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 화장료 조성물을 제공한다. The present invention provides a cosmetic composition comprising the compound represented by Formula 1 or a cosmetically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 피부 미백용, 피부 탄력 증진 또는 주름 개선용, 피부 보습용, 항산화용 또는 피부 트러블 개선용 화장료 조성물을 제공할 수 있다.Specifically, the present invention relates to a cosmetic composition for skin whitening, skin elasticity enhancement or wrinkle improvement, skin moisturizing, antioxidant or skin trouble improving cosmetic comprising the compound represented by the above formula (1) or a cosmetically acceptable salt thereof Composition can be provided.
본 발명에 있어서, “피부 미백”이라 함은 멜라닌 색소의 합성을 저해함으로써 피부 톤을 밝게 할 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 말한다. 본 발명의 일 실시예에서는, 화학식 1로 표시되는 화합물을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)에 첨가한 후 멜라닌 총량을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 양성대조군에 비하여 상당히 우수한 멜라닌 총량 감소 효과를 나타내어, 화학식 1로 표시되는 화합물을 포함하는 조성물은 피부 미백 용도로 사용될 수 있음을 확인하였다(표 1).In the present invention, " skin whitening " refers to not only brightening the skin tone by inhibiting the synthesis of melanin pigment but also improving skin hypercholesterolemia due to ultraviolet rays, hormones or heredity, such as spots or freckles. In one embodiment of the present invention, the compound of Formula 1 was added to mouse melanoma cells (B-16 mouse melanoma cells) and the total amount of melanin was measured. As a result, in the test group to which the compound was added, The composition containing the compound represented by the formula (1) can be used for skin whitening purposes (Table 1).
본 발명에 있어서, “피부 탄력 증진”이란 피부가 쳐지거나 늘어지는 정도를 완화시켜주는 것으로, 엘라스틴으로 구성된 탄력섬유가 콜라겐(collagen)이라고 하는 교원섬유와 함께 존재하는데, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부 탄력이 유지되는 것을 말한다. 본 발명에 있어서, “주름 개선”이란 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. In the present invention, " skin elasticity enhancement " is intended to alleviate the degree to which the skin is stuck or stretched. Elastic fibers composed of elastin are present together with collagen fibers called collagen. Skin elasticity is maintained. In the present invention, " wrinkle improvement " refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already formed wrinkles.
본 발명의 일 실시예에서는, 화학식 1로 표시되는 화합물을 인간 유래 섬유아세포의 배양액에 첨가한 후 콜라겐 합성 촉진 효과를 실험한 결과, 상기 화합물을 첨가한 실험군의 경우 양성대조군에 비하여 같은 농도에서 상당히 우수한 콜라겐 합성 효과를 나타내었다(표 2). In one embodiment of the present invention, the compound represented by the formula (1) was added to a culture solution of human fibroblasts and then the collagen synthesis promoting effect was examined. As a result, in the test group containing the compound, Showed excellent collagen synthesis effect (Table 2).
또한, 본 발명의 일 실시예에서는, 상기 화학식 1로 표시되는 화합물의 엘라스타제 활성 저해 효과를 실험한 결과, 살비아놀산 C를 첨가한 실험군의 경우 우수한 엘라스타제 활성 저해 효과를 나타내었다(표 3). 이를 통해, 화학식 1로 표시되는 화합물을 포함하는 조성물은 피부 탄력 증진 또는 주름 개선 용도로 사용될 수 있음을 확인하였다.In addition, in an embodiment of the present invention, an experiment of inhibiting the elastase activity of the compound represented by the formula (1) showed an excellent inhibitory effect of elastase activity in the test group supplemented with salvianolic acid C Table 3). Thus, it was confirmed that the composition containing the compound represented by Chemical Formula 1 can be used for skin elasticity enhancement or wrinkle improvement.
본 발명에 있어서, “피부 보습”이란 피부에 수분감을 증가시켜주고, 촉촉한 상태를 유지시키는 것을 의미한다. 피부 보습 효과는 피부의 주름개선, 탄력도 증가에 도움을 줄 수 있다. 본 발명의 일 실시예에서는, 상기 화학식 1로 표시되는 화합물의 우수한 콜라겐 합성 효과, 엘라스타제 활성 저해 효과를 나타내었는바, 화학식 1로 표시되는 화합물 포함하는 조성물은 피부 보습 용도로 사용될 수 있음을 확인하였다(표 2 내지 3).In the present invention, " skin moisturizing " means increasing moisture in the skin and maintaining a moist state. Skin moisturizing effect can help to improve wrinkles and elasticity of skin. In one embodiment of the present invention, the compound represented by the formula (1) has excellent collagen synthesis and elastase activity inhibitory effect, so that the composition containing the compound represented by the formula (1) can be used for skin moisturizing (Tables 2 to 3).
본 발명에 있어서, “항산화”란 세포 내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼(free radical) 또는 활성산소종(reactive oxygen species;ROS)에 의한 세포의 산화를 억제하는 것을 말하며, 자유 라디칼 또는 활성산소종을 제거하여 이로 인한 세포의 손상이 감소되는 것을 포함한다. 본 발명의 일 실시예에서는, 화학식 1로 표시되는 화합물의 자유라디칼 소거 활성을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 양성대조군에 비하여 더 우수한 항산화 효과를 나타내었다. 이를 통해 화학식 1로 표시되는 화합물을 포함하는 조성물은 항산화 용도로 사용될 수 있으며, 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용할 수 있음을 확인하였다(표 4).In the present invention, " antioxidant " refers to a compound that inhibits the oxidation of cells with highly reactive free radicals or reactive oxygen species (ROS) depending on the oxidative stress caused by intracellular metabolism or ultraviolet rays. And includes removal of free radicals or reactive oxygen species, thereby reducing damage to the cells. In one embodiment of the present invention, the free radical scavenging activity of the compound represented by Chemical Formula 1 was measured. As a result, the antioxidative activity of the compound to which the compound was added was superior to that of the positive control. Thus, it was confirmed that the composition containing the compound represented by Chemical Formula 1 can be used for antioxidant and can serve as an auxiliary role in skin whitening, elasticity enhancement, wrinkle improvement, and skin moisturization (Table 4).
본 발명에 있어서, “피부 트러블”이란 대식세포에서의 과도한 일산화질소 생성으로 인하여 유발된 염증에 의해 발생할 수 있는 피부질환을 의미한다. 상기 피부 트러블은 염증과 관련된 피부질환이면 그 종류에 관계없이 모두 포함되며, 상기 염증과 관련된 피부질환의 비제한적인 예로는 아토피 피부염, 건선, 방사선, 화학물질, 화상 등에 의해 촉발되는 홍반성 질환, 산 화상, 수포성 피부병, 태선 모양 종류 질환, 알레르기에 기한 가려움증, 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염, 원형 탈모증과 같은 염증성 모발 손실, 피부 T-세포 림프종 등이 있으며, 구체적으로, 피부발진, 여드름, 뾰루지, 주사(빨간 코) 등이 있으나 이에 제한되는 것은 아니다. 또한, 본 발명에서 사용되는 용어, "트러블 개선"이란 피부에 트러블이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 트러블을 완화시키는 것을 말한다. In the present invention, " skin trouble " means a skin disease that can be caused by inflammation caused by excessive nitric oxide production in macrophages. The skin trouble includes all kinds of skin diseases related to inflammation regardless of the type thereof. Non-limiting examples of the skin diseases related to the inflammation include inflammatory diseases caused by atopic dermatitis, psoriasis, radiation, chemical substances, Inflammatory hair loss such as acid burns, watery skin diseases, psoriasis type diseases, allergic itching, seborrheic eczema, rose acne, pemphigus vulgaris, polymorphic exudative erythema, erythema nodosum, Cell lymphoma, and the like. Specific examples include skin rash, acne, rash, injection (red nose), but are not limited thereto. The term "improvement of trouble" as used in the present invention refers to inhibiting or inhibiting the generation of troubles in the skin or alleviating troubles already generated.
본 발명에 있어서, “항염증”이란 염증을 억제하는 것을 말하며, 상기 염증은 어떤 자극에 대한 생체조직의 방어반응의 하나로, 조직 변질, 순환 장애와 삼출, 조직 증식의 세가지를 병발하는 복잡한 병변을 말한다. 보다 구체적으로 염증은 선천성 면역의 일부이며 다른 동물에서처럼 인간의 선천성 면역은 병원체에 특이적으로 존재하는 세포 표면의 패턴을 인식한다. 식세포는 그런 표면을 가진 세포를 비자기로 인식하고 병원체를 공격한다. 만일 병원균이 신체의 물리적 장벽을 깨고 들어온다면 염증반응이 일어난다. 염증반응은 상처부위에 침입한 미생물들에 대한 적대 환경을 만드는 비특이적인 방어작용이다. 염증반응에서, 상처가 나거나 외부 감염체가 체내로 들어왔을 때, 초기단계 면역반응을 맡고 있는 백혈구들이 몰려들어 사이토카인을 발현한다. 따라서 세포 내 사이토카인의 발현양이 염증반응 활성화의 지표가 된다. 본 발명의 항염증은 피부에서 발병된 염증을 억제하는 것일 수 있다.In the present invention, " anti-inflammation " refers to inhibition of inflammation. The inflammation is a defense reaction of biological tissue against a certain stimulus, and includes complicated lesions involving tissue degeneration, circulatory disorder and exudation, and tissue proliferation. It says. More specifically, inflammation is part of congenital immunity and, like in other animals, human congenital immunity recognizes a pattern of cell surfaces that are specifically present in a pathogen. Phagocytes recognize cells with such surfaces as non-magnetic and attack pathogens. If pathogens break through the physical barriers of the body, an inflammatory reaction occurs. Inflammation is a nonspecific defense that creates hostile environments for microorganisms entering the wound. In the inflammatory response, white blood cells that are responsible for the early stage of immune response, when wounded or infected, enter the body to express cytokines. Therefore, the expression level of intracellular cytokine is an index of inflammatory response activation. The antiinflammation of the present invention may be to suppress inflammation caused in the skin.
본 발명의 일 실시예에서는, 화학식 1로 표시되는 화합물의 NO 생성 억제력을 측정한 결과, 상기 화합물을 첨가한 실험군의 경우 양성대조군에 상응하는 정도의 항염증 효과를 나타내었다. 이를 통해 화학식 1로 표시되는 화합물을 포함하는 조성물은 피부 트러블 개선 용도로 사용될 수 있으며, 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용할 수 있음을 확인하였다(표 5).In one embodiment of the present invention, the inhibitory potency of NO formation of the compound represented by Chemical Formula 1 was measured. As a result, the test group to which the compound was added exhibited anti-inflammatory effect to a degree equivalent to that of the positive control. It was confirmed that the composition containing the compound represented by Chemical Formula 1 can be used for improving skin troubles and can act as an auxiliary role in skin whitening, elasticity enhancement, wrinkle improvement, and skin moisturizing (Table 5) .
본 발명에 따른 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition according to the present invention can be used as a cosmetic composition in the form of a solution, an ointment for external use, a cream, a foam, a nutritional lotion, a softening water, a pack, a soft water, an emulsion, a makeup base, But are not limited to, emulsions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays It is not.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier to be incorporated in a general skin cosmetic composition, and examples thereof include oil, water, a surfactant, a moisturizer, A thickening agent, a chelating agent, a coloring matter, an antiseptic, a perfume, and the like may be appropriately compounded, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.The cosmetically acceptable carrier to be contained in the cosmetic composition of the present invention varies depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, a paste, a cream or a gel, the carrier component may be an animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide Mixtures of these may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as the carrier component, Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, 1,3-butyl glycol oil may be used, in particular fatty acid esters of cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycols or sorbitan may be used have.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is a soap, an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, glycerol, .
본 발명의 다른 양태로서, 상기 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염을 포함하는 식품 조성물을 제공한다.In another aspect of the present invention, there is provided a food composition comprising the compound represented by the above-mentioned formula (1) or a pharmaceutically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염을 포함하는 피부 미백용, 피부 탄력 증진 또는 주름 개선용, 피부 보습용, 항산화용, 또는 피부 트러블 개선용 식품 조성물을 제공할 수 있다. 상기 화학식 1로 표시되는 살비아놀산 C 화합물, 피부 미백, 피부 탄력 증진, 주름 개선, 피부 보습, 항산화 및 피부 트러블 개선은 상기에서 설명한 바와 같다. 상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되는 것은 아니다.Specifically, the present invention relates to a method for skin whitening, skin elasticity enhancement or wrinkle improvement, skin moisturizing, antioxidation, or skin trouble improvement comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof Food compositions can be provided. The salvianolic acid C compound represented by Formula 1, skin whitening, skin elasticity enhancement, wrinkle improvement, skin moisturizing, antioxidation, and skin trouble improvement are as described above. The food composition may be used in the form of a health functional food, but is not limited thereto.
본 발명의 식품 조성물에 포함된 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염은 화학식 1로 표시되는 화합물을 포함하는 동식물, 이의 추출물, 이의 분획물 또는 이의 가공물의 형태로 포함될 수 있다. 또한 상기 조성물은 유효성분 이외에 식품학적으로 허용 가능한 식품보조첨가제를 포함할 수 있다.The compound represented by the formula (1) or a pharmaceutically acceptable salt thereof contained in the food composition of the present invention may be contained in the form of an animal or plant including the compound represented by the formula (1), an extract thereof, a fraction thereof or a processed product thereof. The composition may also include a food-acceptable food-aid additive in addition to the active ingredient.
본 발명에 있어서, "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품보조첨가제의 종류가 제한되는 것은 아니다.In the present invention, the term "food-aid additive " means a component that can be added to foods in a supplementary manner, and is appropriately selected and used by those skilled in the art as added to produce health functional foods of each formulation. Examples of food-aid additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, , a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, and a carbonating agent used in a carbonated drink. However, the types of the food auxiliary additives of the present invention are not limited by these examples.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 “기능성”이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부 미백, 피부 탄력 증진 또는 주름 개선, 피부 보습, 항산화 또는 피부 트러블 개선 효과를 증진시키기 위한 보조제로 섭취가 가능하다.A health functional food may be included in the food composition of the present invention. In the present invention, the term "health functional food" refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and rings using raw materials and components having useful functions in the human body. The term "functional" as used herein means that the structure and function of the human body have a beneficial effect on health uses such as controlling nutrients or physiological actions. The health functional food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients that are conventionally added in the art. In addition, the formulations of the above health functional foods may also be manufactured without limitations as long as they are acceptable as health functional foods. The food composition of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has an advantage of being free from side effects that may occur when a food is used as a raw material for a long period of time, and is excellent in portability. The health functional food can be ingested as an adjunct to improve skin whitening, skin elasticity improvement or wrinkle improvement, skin moisturizing, antioxidant or skin trouble improving effect.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 화학식 1로 표시되는 화합물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.The form of the health functional food of the present invention is not limited, and may include all foods in the conventional meaning, and may be used in combination with terms known in the art such as functional foods. In addition, the health functional food of the present invention can be prepared by mixing other suitable auxiliary ingredients, which may be included in food, according to the selection of a person skilled in the art, and known additives. Examples of foods that can be added include dairy products, such as meat, sausage, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Vitamin complex, and the like, and can be prepared by adding to juice, tea, jelly, juice and the like prepared by using the compound represented by the formula (1) according to the present invention as a main component. It also includes foods used as feed for animals.
본 발명의 또 다른 양태로서, 상기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염을 포함하는 의약외품 조성물을 제공한다.As another embodiment of the present invention, there is provided a quasi-drug composition comprising the compound represented by the above-mentioned formula (1) or a pharmaceutically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염을 포함하는 피부 미백용, 피부 탄력 증진 또는 주름 개선용, 피부 보습용, 항산화용, 또는 피부 트러블 개선용 의약외품 조성물을 제공할 수 있다. 상기 화학식 1로 표시되는 살비아놀산 C 화합물, 피부 미백, 피부 탄력 증진, 주름 개선, 피부 보습, 항산화 및 피부 트러블 개선은 상기에서 설명한 바와 같다.Specifically, the present invention relates to a method for skin whitening, skin elasticity enhancement or wrinkle improvement, skin moisturizing, antioxidation, or skin trouble improvement comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof Quasi-drug compositions can be provided. The salvianolic acid C compound represented by Formula 1, skin whitening, skin elasticity enhancement, wrinkle improvement, skin moisturizing, antioxidation, and skin trouble improvement are as described above.
본 발명의 의약외품 조성물에는 상기 성분 외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다.The quasi-drug composition of the present invention may further contain a pharmaceutically acceptable carrier, excipient or diluent as necessary in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as the effect of the present invention is not impaired, and examples thereof include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, .
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다.Representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium Methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oils such as sodium carboxymethylcellulose, , Injectable ester, witepsol, macrogol, tween 61, cacao paper, and laurie paper.
또한, 본 발명의 화학식 1로 표시되는 화합물을 의약외품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 미백, 탄력 증진, 주름 개선, 보습, 항산화 또는 항염증 성분을 포함할 수 있을 것이다. 추가적인 피부 미백, 탄력 증진, 주름 개선, 보습, 항산화 또는 항염증 성분을 포함하게 되면 본 발명의 조성물의 피부 미백, 탄력 증진, 주름 개선, 보습, 항산화 또는 피부 트러블 개선 효과는 더욱 증가될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 상기 의약외품 조성물은 당업계에 공지된 미백 성분으로서, 코즈산(Kojic acid), 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민-C(L-Ascorbic acid); 당업계에 공지된 피부 탄력, 주름 개선 또는 보습 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물; 당업계에 공지된 항산화 성분으로서, 페놀성 화합물, 플라보노이드, 토코페롤, 비타민 C, 셀레늄; 당업계에 공지된 항염증 성분으로서, 비스테로이드계로 플루페남산, 이부프로펜, 벤지다민, 인도메타신, 프레드니솔론, 덱사메타손, 알란토인, 아즈엔, 하이드로코티손; 및 이들의 유도체와 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 피부 안전성, 상기 화학식 1로 표시되는 화합물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.When the compound represented by the formula (1) of the present invention is used as a quasi-drug, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, it may contain known skin whitening, elasticity enhancement, wrinkle improvement, moisturizing, antioxidant or anti-inflammatory ingredients. The skin whitening, elasticity enhancement, wrinkle improvement, moisturizing, antioxidant or skin trouble improving effects of the composition of the present invention can be further increased if the composition further includes skin whitening, elasticity enhancement, wrinkle improvement, moisturizing, antioxidant or anti- . When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. The quasi-drug composition may be a whitening ingredient known in the art, such as a substance inhibiting tyrosinase enzyme activity such as kojic acid, arbutin, hydroquinone, L-ascorbic acid; Retinoic acid, TGF, proteins from animal placenta, betulinic acid and chlorella extract, as skin elasticity, wrinkle or moisturizing ingredients known in the art; Antioxidant components known in the art include phenolic compounds, flavonoids, tocopherols, vitamin C, selenium; As anti-inflammatory ingredients known in the art, there are non-steroid based flufenamic acid, ibuprofen, benzydamine, indomethacin, prednisolone, dexamethasone, allantoin, azene, hydrocortisone; And derivatives thereof, and various plant extracts. ≪ Desc / Clms Page number 2 > The additional ingredient may be contained in an amount of 0.0001% by weight to 10% by weight based on the total weight of the composition, and the content may be adjusted according to requirements such as skin safety, ease of formulation of the compound represented by Formula 1 will be.
본 발명의 의약외품 조성물은 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention can be exemplified by a disinfectant cleaner, a shower foam, a softener solution, a wet tissue, a coating agent, and the like. The formulation method, dosage, usage method, And the like.
또한, 본 발명의 상기 화학식 1로 표시되는 화합물은 개체의 피부에 도포하는 단계를 포함하는, 피부 미백, 피부 탄력 증진 또는 주름 개선, 피부 보습, 항산화 또는 피부 트러블 개선 방법에 사용될 수 있다. 상기 개체는 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함한다.In addition, the compound represented by Formula 1 of the present invention can be used for skin whitening, skin elasticity enhancement or wrinkle improvement, skin moisturizing, antioxidant or skin trouble improvement method including a step of applying to the individual's skin. The subject includes, without limitation, mammals including rats, livestock, humans, and the like.
본 발명의 살비아놀산 C 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물은 피부 미백, 탄력 증진 또는 주름 개선, 피부 보습, 항산화, 피부 트러블 개선 효능이 우수하다. 구체적으로 본 발명의 조성물은 저농도에서도 뛰어난 멜라닌 총량 감소 효과를 나타내고 콜라겐 합성 촉진 효과, 엘라스타제 활성 저해 효과가 우수하며, 항산화, 항염증 및 항당화 효과가 우수하여 피부 미백용, 탄력 증진용 또는 주름 개선용, 피부 보습용, 항산화용 및 피부 트러블 개선용 화장료 조성물로서의 활용도가 높다. 또한, 본 발명의 살비아놀산 C를 포함하는 조성물은 식품 조성물 및 의약외품 조성물로서 사용할 수 있다.The cosmetic composition comprising salvianolic acid C of the present invention or a cosmetically acceptable salt thereof as an active ingredient is excellent in skin whitening, elasticity enhancement or wrinkle improvement, skin moisturizing, antioxidation and skin troubles. Specifically, the composition of the present invention is excellent in antioxidant, antiinflammatory and anti-glycosylation effects, exhibiting excellent melanin total amount reduction effect at low concentration, promoting collagen synthesis, inhibiting elastase activity, It is highly utilized as a cosmetic composition for wrinkle improvement, skin moisturizing, antioxidation and skin trouble improvement. In addition, the composition containing salvianolic acid C of the present invention can be used as a food composition and a quasi-drug composition.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다.Hereinafter, the constitution and effects of the present invention will be described in more detail through examples. These embodiments are only for illustrating the present invention, and the scope of the present invention is not limited by these embodiments.
참조예Reference Example 1 : One : 살비아놀산Salvianolic acid C( C ( SalvianolicSalvianolic acid C) 물질 정보 acid C) Material Information
[화학식 1][Chemical Formula 1]
물질명 : Salvianolic acid CMaterial name: Salvianolic acid C
CAS No. : 115841-09-3CAS No. : 115841-09-3
분자식 : C26H20O10 Molecular formula: C 26 H 20 O 10
분자량 : 492.44Molecular weight: 492.44
구입처 : CHENGDU MUST BIO-TECHNOLOGY CO., LTD. Where to Buy: CHENGDU MUST BIO-TECHNOLOGY CO., LTD.
실험예Experimental Example 1 : 세포 수준에서의 멜라닌 총량 감소 효과에 따른 미백 효과 1: Whitening effect according to the decrease effect of melanin total amount at the cell level
상기 화학식 1의 화합물을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 세포 수준에서의 멜라닌 총량을 측정함으로써 미백 효과를 확인하였다(Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980). 실험 전 쥐의 멜라노마 세포에 대하여 독성을 평가하여 독성이 없는 농도를 선정하여 미백 평가를 수행하였다.The compound of Formula 1 was added to the culture medium of mouse B-16 mouse melanoma cells to determine the whitening effect by measuring the total amount of melanin at the cellular level (Lotan R., Lotan D. Cancer Res . 40 : 3345-3350, 1980). To evaluate the toxicity of melanoma cells in rats before the experiment, whitening evaluation was performed by selecting a concentration that is not toxic.
화학식 1의 화합물을 배양액에 최종 농도가 1 ppm 또는 20 ppm이 되도록 하였으며, 대조군인 셀리나는 20 ppm이 되도록 첨가하여 각각 B-16 멜라노마 세포에 처리한 후 3일간 배양하였다.The compound of formula (I) was added to the culture to a final concentration of 1 ppm or 20 ppm, and the control group, Celina, was added to 20 ppm, and treated with B-16 melanoma cells, followed by culturing for 3 days.
이후, 세포들을 트립신(trypsin) 처리하여 배양용기로부터 떼어내 원심분리한 후, 멜라닌을 추출하였다. 떼어낸 세포는 수산화나트륨 용액(1N 농도) 1 ml를 가하여 10 분간 끓여 멜라닌을 녹이고 분광 광도계를 이용하여 400 nm에서 흡광도를 측정함으로써 생성된 멜라닌의 양을 측정하였다.Cells were then trypsinized, detached from the culture, centrifuged, and then melanin was extracted. The removed cells were incubated with 1 ml of sodium hydroxide solution (1N concentration), boiled for 10 minutes to dissolve melanin, and the amount of melanin produced was measured by measuring the absorbance at 400 nm using a spectrophotometer.
상기 멜라닌 양은 단위 세포수당(1×106 cell)의 흡광도로 나타내는 방법으로 측정하였으며, 음성대조군에 대한 상대적인 멜라닌 총량을 저해율(%)로 계산하고 결과를 하기 표 1에 정리하였다.The amount of melanin was measured by the absorbance of 1 × 10 6 cells per unit cell, and the total amount of melanin relative to the negative control was calculated as the inhibition rate (%). The results are summarized in Table 1 below.
상기 표 1의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 양성대조군인 셀리나와 비교했을 때, 같은 농도인 20 ppm에서도 상당히 우수한 멜라닌 총량 감소 효과를 나타내어, 피부 미백 용도로 사용할 수 있음을 알 수 있었다.As can be seen from the results shown in Table 1, the compound of Chemical Formula 1 showed a remarkably superior total melanin reduction effect even at the same concentration of 20 ppm, as compared with the positive control, Celina, and thus it could be used for skin whitening .
실험예Experimental Example 2 : 인체 유래의 섬유아세포에서 제1형 콜라겐(type Ⅰ collagen) 합성 촉진 효과 2: promoting the synthesis of type I collagen in human fibroblasts
화학식 1의 화합물을 인간 유래 섬유아세포의 배양액에 첨가하여 세포 수준에서 제1형 콜라겐 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type Ⅰ C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다. 콜라겐 합성량을 측정하기 위해 화학식 1의 화합물을 섬유아세포의 배양배지(DMEM 배지)에 첨가하여 48 시간 배양한 후 배양액을 취하여 PICP EIA 키트로 저농도에서 제1형 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다.The compound of Chemical Formula 1 was added to the culture medium of human-derived fibroblasts to confirm the promoting effect of type I collagen synthesis at the cellular level. The collagen synthesis was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay Kit). To measure the amount of collagen synthesis, the compound of formula (I) was added to a culture medium of fibroblasts (DMEM medium) and cultured for 48 hours. The culture broth was taken and the degree of type 1 collagen synthesis was measured at low concentration using a PICP EIA kit using a spectrophotometer And measured at 450 nm.
효과의 비교를 위하여 시료를 처리하지 않은 섬유아세포의 배양배지(음성대조군)와 비타민 C(양성대조군)를 최종농도 52.85 μg/ml 가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. 콜라겐 생성 증가율은 대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하고 결과를 하기 표 2에 나타내었다.For the comparison of the effects, the degree of collagen synthesis was measured in the same manner for the samples in which the culture medium of the untreated fibroblasts (negative control) and vitamin C (positive control) were added to a final concentration of 52.85 μg / ml. The increase rate of collagen production was calculated as a ratio of relative collagen production to the control group, and the results are shown in Table 2 below.
상기 표 2의 결과에서 볼 수 있듯이, 화학식 1의 화합물을 처리한 경우, 농도 의존적으로 콜라겐 합성이 증가되었고, 일반적으로 콜라겐 합성을 유도하는 것으로 잘 알려진 비타민 C를 적용한 경우와 비교해 같은 농도인 50 ppm에서 우수한 콜라겐 합성 효과를 나타내었다. 따라서, 화학식 1의 화합물은 피부 탄력 증진, 주름 개선 또는 피부 보습 용도로 사용할 수 있음을 알 수 있었다. As can be seen from the results in Table 2, when the compound of Chemical Formula 1 was treated, the collagen synthesis was increased in a concentration-dependent manner, and compared with the case of vitamin C, which is generally known to induce collagen synthesis, Showed excellent collagen synthesis effect. Thus, it has been found that the compound of formula (I) can be used for skin elasticity enhancement, wrinkle improvement or skin moisturizing.
실험예Experimental Example 3 : 3: 엘라스타제Elastase 활성 저해 효과 ( Active inhibition effect ( 반복수Number of repeats = 3) = 3)
엘라스틴(elastin)을 분해하는 효소인 엘라스타제(elastase)의 활성 저해 효과를 다음과 같이 확인하였다.The activity inhibition effect of elastase, an enzyme that degrades elastin, was confirmed as follows.
엘라스타제(elastase)는 사람의 백혈구 세포로부터 유래한 것을 사용하였고, 엘라스타제의 기질로 합성 기질인 MeOSuc-Ala-Ala-Pro-Val-pNA를 사용하였다. 완충용액은 100 mM의 Tris (pH 7.5) 용액을 사용하였다. 엘라스타제는 완충용액을 이용하여 최종적으로 0.2 mU 을 사용하였다. 또한 엘라스타제의 합성 기질은 DMSO를 이용하여 100 mM 용액을 만든 후 최종 농도가 0.5 mM이 되도록 완충용액을 이용하여 희석하였다. 이 때, 양성 대조군은 엘라스테이즈 저해 물질로 알려진 퀘르세틴(Quercetin)을 10 ppm 농도로 넣은 것으로 설정하였다. 엘라스타제 저해 후보인 화학식 1의 화합물은 최종농도가 10, 20 ppm이 되도록 첨가하였다. 반응은 96-웰 플레이트에서 진행하였으며, 상온에서 20 분간 반응시켰다. 분광 광도계를 이용하여 1 분 간격으로 405 nm에서 흡광도를 측정하여, 시간 대비 흡광도의 기울기를 구하여 효소의 활성도를 측정하였다. 엘라스타제 저해율은 다음과 같이 계산하였으며, 그 결과는 하기 표 3에 나타내었다.Elastase was derived from human leukocyte cells and MeOSuc-Ala-Ala-Pro-Val-pNA, a synthetic substrate, was used as a substrate for elastase. The buffer solution used was 100 mM Tris (pH 7.5) solution. Elastase was finally used at 0.2 mU using a buffer solution. The synthetic substrate of elastase was diluted with buffer to make a final concentration of 0.5 mM after making 100 mM solution using DMSO. At this time, the positive control group was set to contain 10 ppm of quercetin, which is known as an ELASASTE inhibitor. The compound of formula (1), which is an inhibitor of elastase inhibition, was added to give a final concentration of 10, 20 ppm. The reaction was carried out in a 96-well plate and allowed to react at room temperature for 20 minutes. The absorbance was measured at 405 nm using a spectrophotometer at intervals of 1 minute, and the slope of the absorbance versus time was measured to determine the activity of the enzyme. Elastase inhibition rates were calculated as follows, and the results are shown in Table 3 below.
상기 표 3의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 양성대조군과 비교해 대등한 효과를 보이며, 대조군에 대비해서 엘라스타제 활성 저해 효과가 우수함을 확인하였다. 따라서, 화학식 1의 화합물은 피부 탄력 증진, 주름 개선 또는 피부 보습 용도로 사용할 수 있음을 알 수 있었다. As can be seen from the results of Table 3, the compound of Chemical Formula 1 showed an equivalent effect as compared with the positive control, and it was confirmed that the compound of the formula 1 had an excellent inhibitory effect on elastase activity as compared with the control. Thus, it has been found that the compound of formula (I) can be used for skin elasticity enhancement, wrinkle improvement or skin moisturizing.
실험예Experimental Example 4 : 항산화 효과 - 자유라디칼 소거율 4: Antioxidant effect - Free radical scavenging rate
화학식 1의 화합물의 항산화 작용을 확인하기 위해 자유라디칼 소거 활성을 측정하였다. 자유라디칼 소거 활성은 DPPH를 이용하여 측정하였다. DPPH는 시그마사(Sigma Co., Ltd, 미국)에서 구입하여 사용하였다. 먼저, 1.5 mM (0.06 mg/ml)의 표준 DPPH 에탄올 용액을 만들었다. 그리고, 3차 증류수를 이용하여 1000 μg/ml 비타민 C 용액을 만든 다음 1/2씩 연속 희석하여 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.90625, 1.953125, 0.9765625, 0.48828125 μg/ml 농도의 비타민 C 시료를 만들었다. 또한 비타민 C와 동일한 농도로 화학식 1의 화합물의 희석액을 준비하였다. 그 다음, 상기 시료와 표준 DPPH 용액을 같은 비율로 첨가하여 잘 교반한 후, 37 ℃에서 30 분간 반응시키고 520 ㎚에서 흡광도를 측정하였다. 이때, 상기 시료 대신 에탄올을 첨가한 것을 대조군으로 하였다. 자유라디칼 소거능은 half maximal inhibitory concentration(억제 중간 값)인 IC50을 구하여 그 결과를 하기 표 4에 나타내었다. IC50은 무첨가 대조군의 자유라디칼을 50% 제거하는데 필요한 비타민 C 및 화학식 1의 화합물의 농도로써 자유라디칼 소거능을 표현하는 일반적인 방법이다.The free radical scavenging activity was measured to confirm the antioxidative activity of the compound of formula (1). Free radical scavenging activity was measured using DPPH. DPPH was purchased from Sigma Co. (Sigma Co., Ltd, USA) and used. First, a standard DPPH ethanol solution of 1.5 mM (0.06 mg / ml) was prepared. Then, a 1000 μg / ml vitamin C solution was prepared using the third distilled water, and then serially diluted with 1/2 of the diluted solution to obtain 1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.90625, 1.953125, 0.9765625, 0.48828125 μg / ml of vitamin C sample. A dilution of the compound of formula (1) was also prepared at the same concentration as vitamin C. Then, the sample and standard DPPH solution were added at the same ratio, stirred well, reacted at 37 ° C for 30 minutes, and absorbance was measured at 520 nm. At this time, ethanol was added instead of the sample to give a control group. IC 50 , which is half maximal inhibitory concentration (inhibition value), was determined for the free radical scavenging ability, and the results are shown in Table 4 below. IC 50 is a common method for expressing free radical scavenging activity with the concentration of vitamin C and the compound of formula 1 required to remove 50% of the free radicals of the no-added control group.
상기 표 4의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 일반적으로 항산화 물질로 알려진 비타민 C를 적용한 경우보다 더 낮은 IC50 값을 지님을 알 수 있었다. 따라서, 화학식 1의 화합물은 우수한 항산화 효과를 나타내어, 항산화 용도로 사용할 수 있으며, 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용하여 상승효과를 기대할 수 있음을 알 수 있었다.As can be seen from the results in Table 4, the compound of Chemical Formula 1 has a lower IC 50 value than vitamin C, which is generally known as an antioxidant. Therefore, the compound of the formula (1) exhibits excellent antioxidative effect and can be used for antioxidative use, and it can be expected that a synergistic effect can be expected by acting as an auxiliary role in skin whitening, elasticity enhancement, wrinkle improvement and skin moisturizing .
실험예Experimental Example 5 : 항염증 효과 - NO 생성 억제 효과 5: Anti-inflammatory effect - NO production inhibitory effect
화학식 1의 화합물의 항염증 효과 및 피부 트러블 개선 효과를 확인하기 위하여 RAW264.7 세포주 (ATCC number: CRL-2278)를 이용한 GRIESS 법으로 일산화질소(NO) 형성 억제 실험을 실시하였다.In order to confirm the antiinflammatory effect and the skin trouble-improving effect of the compound of Chemical Formula 1, nitric oxide (NO) formation inhibition experiment was performed by the GRIESS method using RAW264.7 cell line (ATCC number: CRL-2278).
구체적으로, 생쥐의 대식세포인 RAW264.7 세포를 수차례 계대 배양하고, 상기 배양된 세포를 웰 하나에 3×105 개씩 들어가도록 24-웰 플레이트에 넣은 후, 24 시간 동안 배양시켰다. 이어서, 하기 표 5에 나타난 농도로 희석된 화학식 1의 화합물을 함유한 세포 배지로 교체하였다. 이 때, NO-생성 억제물질인 L-NMMA(L-NG-모노메틸아르기닌, L-NG-Monomethylarginine)을 양성대조군으로 함께 처리하여 30분 동안 배양하였고, 자극원으로 LPS(Lipopolysaccharide)를 1 ㎍씩 처리하여 24시간 동안 배양하였다. 상층액을 100 ㎕씩 취해 96-웰 프레이트에 옮기고, GRIESS 용액을 100 ㎕씩 가해 상온에서 10분간 반응시킨 후, 540 nm에서의 흡광도를 측정함으로써 화학식 1의 화합물의 NO 억제 효과를 판단하고, 그 결과를 하기 표 5에 나타내었다.Specifically, RAW264.7 cells, macrophages of mice, were subcultured several times, and the cultured cells were put into 24-well plates so as to enter 3 × 10 5 cells into one well, followed by culturing for 24 hours. Subsequently, the cell culture medium containing the compound of the formula (1) diluted to the concentration shown in the following Table 5 was replaced. At this time, L-NMMA (L-NG-monomethylarginine), a NO-production inhibitor, was treated together as a positive control and cultured for 30 minutes. Lipopolysaccharide (LPS) And cultured for 24 hours. 100 μl of the supernatant was transferred to a 96-well plate, and 100 μl of GRIESS solution was added thereto at room temperature for 10 minutes. Then, the absorbance at 540 nm was measured to determine the NO inhibitory effect of the compound of formula The results are shown in Table 5 below.
상기 표 5의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 대표적인 항염 물질인 L-NMMA과 비교해 상응하는 NO 생성 억제율을 나타내며, 대조군과 비교했을 때 우수한 항염증 효과가 있음을 알 수 있었다. 따라서, 화학식 1의 화합물은 피부 트러블 개선 용도로 사용할 수 있으며, 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용하여 상승효과를 기대할 수 있음을 알 수 있었다.As can be seen from the results of Table 5, the compound of Chemical Formula 1 showed a corresponding inhibition of NO production as compared with L-NMMA, which is a representative anti-inflammatory substance, and showed excellent anti-inflammatory effect as compared with the control group. Therefore, the compound of Chemical Formula (1) can be used for improving skin troubles, and it can be expected that synergistic effect can be expected by acting as an auxiliary role in skin whitening, elasticity enhancement, wrinkle improvement and skin moisturization.
실험예Experimental Example 6 : 6: 항당화Antialcification (anti-(anti- glycationglycation ) 효과) effect
항당화(anti-glycation) 효능을 확인하기 위하여, L-아르기닌(arginine)과 포도당을 이용하여 항당화 활성을 측정하였다.In order to confirm anti-glycation efficacy, anti-glycation activity was measured using L-arginine and glucose.
먼저, 1M 인산 완충용액(pH 7.4)을 이용하여 1M L-아르기닌(arginine), 1M 포도당을 녹여 준비하고 1M 인산 완충용액을 이용하여 시료를 25, 50 ppm이 되도록 희석해서 준비하였다. 1M L-아르기닌과 1M 인산 완충용액을 1 대 4의 비율로 섞은 다음 96-웰 플레이트에 80 μl씩 분주하였다. 여기에 각각 25, 50 ppm으로 희석한 시료와 양성 대조군으로 사용될 0.01M 아미노구아니딘(aminoguanidin)을 100 μl씩 첨가하였다. 이 시료들을 잘 섞어준 다음, 마지막으로 포도당의 최종 농도가 0.1M이 되도록 1M 인산 완충용액으로 희석한 포도당을 넣은 후, 70 ℃에서 4 시간 동안 반응시켰다. 96-웰 플레이트를 분광 광도계를 이용하여 420 nm에서 흡광도를 측정하여 당화 정도를 측정하였다.First, 1 M L-arginine and 1 M glucose were dissolved in 1 M phosphate buffer (pH 7.4) and diluted to 25 and 50 ppm with 1M phosphate buffer solution. 1M L-arginine and 1M phosphate buffer solution were mixed at a ratio of 1: 4, and then 80 [mu] l each was added to a 96-well plate. To this was added 100 μl of 0.01 M aminoguanidine to be used as a positive control and a sample diluted to 25 and 50 ppm, respectively. These samples were mixed well, and finally glucose was added to 1 M phosphate buffer solution so that the final concentration of glucose was 0.1 M, followed by reaction at 70 ° C for 4 hours. The degree of saccharification was measured by measuring the absorbance of the 96-well plate at 420 nm using a spectrophotometer.
하기 식의 당화(glycation) 실험군은 1M L-아르기닌과 1M 포도당을 넣어 당화를 유발시킨 실험군이며, 시료 자체의 흡광도를 측정하기 위해서 포도당을 넣지 않고 1M L-아르기닌과 시료만을 넣어 420 nm에서 흡광도를 측정하였다. 당화 저해 활성은 다음과 같은 식으로 구하였으며, 그 결과는 하기 표 6에 나타내었다.In order to measure the absorbance of the sample itself, 1M L-arginine and the sample alone were added without glucose, and the absorbance at 420 nm was measured by adding 1M L-arginine and 1M glucose to the glycation test group. Respectively. The saccharide inhibitory activity was determined by the following equation, and the results are shown in Table 6 below.
상기 표 6의 결과에서 볼 수 있듯이, 화학식 1의 화합물은 항당화 물질로 알려진 아미노구아니딘과 비교할 때, 항당화 효과가 더욱 뛰어남을 알 수 있었다. 따라서, 화학식 1의 화합물은 우수한 항당화 효과를 나타내어, 피부 미백, 탄력 증진, 주름 개선 및 피부 보습에 있어, 보조적인 역할로 작용하여 상승효과를 기대할 수 있음을 알 수 있었다.As can be seen from the results of Table 6 above, the compound of Chemical Formula 1 was found to be more excellent in antagonism effect as compared with amino guanidine, which is known as an anticarious substance. Therefore, the compound of the formula (1) shows an excellent antagonism effect, and it can be expected that a synergistic effect can be expected by acting as an auxiliary role in skin whitening, elasticity enhancement, wrinkle improvement and skin moisturization.
Claims (11)
[화학식 1]
[Chemical Formula 1]
The cosmetic composition according to claim 1, wherein the cosmetic composition is for skin whitening.
The cosmetic composition according to claim 1, wherein the cosmetic composition is for enhancing skin elasticity or improving wrinkles.
The cosmetic composition according to claim 1, wherein the cosmetic composition is for skin moisturizing.
The cosmetic composition according to claim 1, wherein the cosmetic composition is for improving skin troubles.
6. The cosmetic composition according to any one of claims 1 to 5, wherein the composition has a total amount of melanin, promotes collagen synthesis, inhibits elastase activity, has antioxidant, anti-inflammatory or antagonistic effect.
The composition according to any one of claims 1 to 5, wherein the composition is at least one selected from the group consisting of a solution, an ointment, a cream, a foam, a nutritional lotion, a softening longevity pack, a pack, a soft water, an emulsion, a makeup base, , Sunscreen creams, sun oil, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays ≪ / RTI >
[화학식 1]
1. A food composition comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]
9. The composition of claim 8, wherein the food composition is for skin whitening; For improving skin elasticity or improving wrinkles; For skin moisturizing; Or for improving skin troubles.
[화학식 1]
A quasi-drug composition comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[Chemical Formula 1]
11. The composition according to claim 10, wherein the quasi-drug composition is used for skin whitening; For improving skin elasticity or improving wrinkles; For skin moisturizing; Or for improving skin troubles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160114536A KR102629000B1 (en) | 2016-09-06 | 2016-09-06 | Composition for skin improvement containing Salvianolic acid C |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160114536A KR102629000B1 (en) | 2016-09-06 | 2016-09-06 | Composition for skin improvement containing Salvianolic acid C |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180027213A true KR20180027213A (en) | 2018-03-14 |
| KR102629000B1 KR102629000B1 (en) | 2024-01-25 |
Family
ID=61660186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160114536A KR102629000B1 (en) | 2016-09-06 | 2016-09-06 | Composition for skin improvement containing Salvianolic acid C |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102629000B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190126954A (en) | 2018-05-02 | 2019-11-13 | 주식회사 마크로케어 | Capsule comprising salvianolic acid and the use of the same |
| KR20190135263A (en) | 2018-05-28 | 2019-12-06 | 충남대학교산학협력단 | Composition comprising salvianolic acid A for preventing or treating for inflammatory skin diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423310A (en) | 2012-01-04 | 2012-04-25 | 中国药科大学 | Application of salvianolic acid C in preparation of drugs for prevention and treatment of hyperuricemia |
| CN102895308B (en) * | 2012-11-13 | 2014-05-14 | 孙海峰 | New application of B Salvianolic acid taken as cosmetics additives with functions of whitening skin, removing freckle and resisting wrinkle |
-
2016
- 2016-09-06 KR KR1020160114536A patent/KR102629000B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423310A (en) | 2012-01-04 | 2012-04-25 | 中国药科大学 | Application of salvianolic acid C in preparation of drugs for prevention and treatment of hyperuricemia |
| CN102895308B (en) * | 2012-11-13 | 2014-05-14 | 孙海峰 | New application of B Salvianolic acid taken as cosmetics additives with functions of whitening skin, removing freckle and resisting wrinkle |
Non-Patent Citations (2)
| Title |
|---|
| European Journal of Medicinal Chemistry, Vol.124, 2016, 637-648. 1부.* * |
| Journal of Ethnopharmacology, Vol.174, 2015, 270-276. 1부.* * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190126954A (en) | 2018-05-02 | 2019-11-13 | 주식회사 마크로케어 | Capsule comprising salvianolic acid and the use of the same |
| KR20190135263A (en) | 2018-05-28 | 2019-12-06 | 충남대학교산학협력단 | Composition comprising salvianolic acid A for preventing or treating for inflammatory skin diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102629000B1 (en) | 2024-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180061664A (en) | Composition for skin improvement containing demethylzeylasteral | |
| KR20180090122A (en) | Composition for skin improvement containing isosakuranetin | |
| KR102629000B1 (en) | Composition for skin improvement containing Salvianolic acid C | |
| KR102639155B1 (en) | Composition for skin improvement containing valechlorine | |
| KR20180090123A (en) | Composition for skin improvement containing liquidambaric lactone | |
| KR20180061662A (en) | Composition for skin improvement containing anemoside A3 | |
| KR20180061663A (en) | Composition for skin improvement containing dehydroevodiamine | |
| KR102662256B1 (en) | Composition for skin improvement containing Syringaresnol-4-O-β-D-apiofuranosy | |
| KR102662257B1 (en) | Composition for skin improvement containing rebaudioside C | |
| KR102664892B1 (en) | Composition for skin improvement containing tenuifoliside A | |
| KR102628373B1 (en) | Composition for skin improvement containing dracorhodin perochlorate | |
| KR102636983B1 (en) | Composition for skin improvement containing isodemethylwedelolactone | |
| KR102665307B1 (en) | Composition for skin improvement containing acetylcimigenol arabinoside | |
| KR20180003920A (en) | Composition for skin improvement containing liriopesides B | |
| KR20180042706A (en) | Composition for skin improvement containing tussilagone | |
| KR20180060728A (en) | Composition for skin improvement containing quercetin-3-O-sophoroside | |
| KR102700608B1 (en) | Composition for skin improvement containing rehmapicroside | |
| KR102644106B1 (en) | Composition for skin improvement containing corytuberine | |
| KR102662255B1 (en) | Composition for skin improvement containing sinigrin | |
| KR102665305B1 (en) | Composition for skin improvement containing swertisin | |
| KR20180061660A (en) | Composition for skin improvement containing thermopsine | |
| KR102644107B1 (en) | Composition for skin improvement containing vomicine | |
| KR20170080082A (en) | Composition for improving skin conditions comprising Polygalaxanthone Ⅲ | |
| KR20160019817A (en) | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN WHITENING, ELASTICITY, ANTI-WRINKLE, SKIN MOISTURIZING OR ANTI-INFLAMMATION COMPRISING α-CYPERONE | |
| KR20180060719A (en) | Composition for skin improvement containing narcissoside |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |